Tove Wästerlid

555 total citations
28 papers, 280 citations indexed

About

Tove Wästerlid is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Tove Wästerlid has authored 28 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 8 papers in Neurology. Recurrent topics in Tove Wästerlid's work include Lymphoma Diagnosis and Treatment (19 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (6 papers). Tove Wästerlid is often cited by papers focused on Lymphoma Diagnosis and Treatment (19 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (6 papers). Tove Wästerlid collaborates with scholars based in Sweden, Denmark and United States. Tove Wästerlid's co-authors include Mats Jerkeman, Karin E. Smedby, Sandra Eloranta, Hans Hagberg, Peter de Nully Brown, Oskar Hagberg, Sara Ekberg, Lars Møller Pedersen, Francesco d’Amore and Ingrid Glimelius and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Cancer.

In The Last Decade

Tove Wästerlid

26 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tove Wästerlid Sweden 9 176 121 67 66 44 28 280
Francesca Palombi Italy 9 181 1.0× 125 1.0× 55 0.8× 113 1.7× 29 0.7× 18 321
Florence Broussais‐Guillaumot France 9 228 1.3× 153 1.3× 95 1.4× 57 0.9× 16 0.4× 14 305
Rafael Dezen Gaiolla Brazil 8 218 1.2× 187 1.5× 64 1.0× 34 0.5× 53 1.2× 20 362
Anna Wall United States 4 180 1.0× 102 0.8× 53 0.8× 47 0.7× 28 0.6× 7 225
Jean-François Larouche Canada 8 163 0.9× 118 1.0× 84 1.3× 46 0.7× 16 0.4× 22 273
Granada Perea Spain 8 91 0.5× 74 0.6× 51 0.8× 29 0.4× 15 0.3× 12 278
Vittorio Ruggero Zilioli Italy 10 156 0.9× 125 1.0× 112 1.7× 61 0.9× 9 0.2× 33 329
Catherine Vézina Canada 7 43 0.2× 169 1.4× 30 0.4× 74 1.1× 30 0.7× 12 295
Kenneth D. Herbst United States 8 148 0.8× 45 0.4× 87 1.3× 80 1.2× 18 0.4× 14 358
Fabrice Jardin France 9 110 0.6× 81 0.7× 61 0.9× 15 0.2× 58 1.3× 22 277

Countries citing papers authored by Tove Wästerlid

Since Specialization
Citations

This map shows the geographic impact of Tove Wästerlid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tove Wästerlid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tove Wästerlid more than expected).

Fields of papers citing papers by Tove Wästerlid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tove Wästerlid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tove Wästerlid. The network helps show where Tove Wästerlid may publish in the future.

Co-authorship network of co-authors of Tove Wästerlid

This figure shows the co-authorship network connecting the top 25 collaborators of Tove Wästerlid. A scholar is included among the top collaborators of Tove Wästerlid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tove Wästerlid. Tove Wästerlid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Adami, Hans‐Olov, et al.. (2025). Association of Pre‐Diagnostic Clonal Hematopoiesis of Indeterminate Potential With Prognosis Among Patients With Cancer. American Journal of Hematology. 100(11). 1993–2003.
2.
Liu, Qianwei, et al.. (2025). Clonal hematopoiesis of indeterminate potential and risk of immune thrombocytopenia. Journal of Internal Medicine. 297(6). 672–682. 1 indexed citations
3.
Glimelius, Ingrid, Sara Ekberg, Karin E. Smedby, & Tove Wästerlid. (2024). Stable use of radiotherapy in lymphoma patients over time – A comprehensive national overview of radiotherapy use in Sweden with focus on older patients. Clinical and Translational Radiation Oncology. 46. 100785–100785. 3 indexed citations
4.
Liu, Qianwei, et al.. (2024). Clonal hematopoiesis of indeterminate potential and the risk of pulmonary embolism: an observational study. EClinicalMedicine. 74. 102753–102753. 6 indexed citations
5.
Ekberg, Sara, et al.. (2024). Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study. Acta Oncologica. 63. 164–168. 2 indexed citations
6.
Bæch, Joachim, Simon Husby, Kristian Kragholm, et al.. (2023). Cardiovascular diseases after high‐dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population‐based study. British Journal of Haematology. 204(3). 967–975. 3 indexed citations
7.
Weibull, Caroline E., Tove Wästerlid, Björn E. Wahlin, et al.. (2023). Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden. HemaSphere. 7(3). e838–e838. 5 indexed citations
8.
Haider, Z., Tove Wästerlid, Leily Rabbani, et al.. (2023). Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study. Frontiers in Oncology. 13. 1176698–1176698. 5 indexed citations
9.
Radkiewicz, Cecilia, Caroline E. Weibull, Henrik Frederiksen, et al.. (2022). Sex differences in lymphoma incidence and mortality by subtype: A population‐based study. American Journal of Hematology. 98(1). 23–30. 32 indexed citations
10.
Smedby, Karin E., et al.. (2022). Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach. Frontiers in Oncology. 12. 984021–984021. 7 indexed citations
11.
Wästerlid, Tove, et al.. (2022). Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data. British Journal of Cancer. 127(10). 1808–1815. 18 indexed citations
12.
Wästerlid, Tove, Lucia Cavelier, Claudia Haferlach, et al.. (2022). Application of precision medicine in clinical routine in haematology—Challenges and opportunities. Journal of Internal Medicine. 292(2). 243–261. 17 indexed citations
13.
Ekberg, Sara, et al.. (2021). Statin use and survival in 16 098 patients with non‐Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. British Journal of Haematology. 195(4). 552–560. 4 indexed citations
14.
Lundin, Jeanette, Tove Wästerlid, Håkan Mellstedt, et al.. (2021). Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. SHILAP Revista de lepidopterología. 2(3). 525–529. 1 indexed citations
15.
Ekberg, Sara, et al.. (2020). Statin use is associated with improved survival in multiple myeloma: A Swedish population‐based study of 4315 patients. American Journal of Hematology. 95(6). 652–661. 26 indexed citations
16.
Wästerlid, Tove, Therése Andersson, Sara Ekberg, et al.. (2020). Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma. American Journal of Hematology. 95(7). 740–748. 12 indexed citations
17.
Wästerlid, Tove, Kim Oren Gradel, Sandra Eloranta, et al.. (2020). Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. British Journal of Haematology. 192(3). 551–559. 7 indexed citations
18.
19.
20.
Wästerlid, Tove, Peter de Nully Brown, Oskar Hagberg, et al.. (2013). Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Annals of Oncology. 24(7). 1879–1886. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Palombi Breakdown of academic impact, for papers by Florence Broussais‐Guillaumot Breakdown of academic impact, for papers by Rafael Dezen Gaiolla Breakdown of academic impact, for papers by Anna Wall Breakdown of academic impact, for papers by Jean-François Larouche Breakdown of academic impact, for papers by Granada Perea Breakdown of academic impact, for papers by Vittorio Ruggero Zilioli Breakdown of academic impact, for papers by Catherine Vézina Breakdown of academic impact, for papers by Kenneth D. Herbst Breakdown of academic impact, for papers by Fabrice Jardin
Rankless by CCL
2026